FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+26.79%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.4B
AUM Growth
+$12.4B
(+14%)
Cap. Flow
-$730M
Cap. Flow
% of AUM
-5.86%
Top 10 Holdings %
Top 10 Hldgs %
33.25%
Holding
138
New
31
Increased
25
Reduced
37
Closed
17
Top Buys
| 1 |
T-Mobile US
TMUS
|
$360M |
| 2 |
Aon
AON
|
$331M |
| 3 |
WUBA
58.COM INC
WUBA
|
$268M |
| 4 |
Bristol-Myers Squibb
BMY
|
$213M |
| 5 |
TIF
Tiffany & Co.
TIF
|
$186M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$1.65B |
| 2 |
Cigna
CI
|
$141M |
| 3 |
General Dynamics
GD
|
$139M |
| 4 |
Fidelity National Information Services
FIS
|
$138M |
| 5 |
Wabtec
WAB
|
$115M |
Sector Composition
| 1 | Healthcare | 42.69% |
| 2 | Communication Services | 18.47% |
| 3 | Technology | 10.46% |
| 4 | Financials | 7.55% |
| 5 | Industrials | 3.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Grifois
GRFS
$6.78B
| $56.8M | 0.45% | 3,113,222 | – | – |
|
|
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $56.7M | 0.45% | +900,000 | New | +$56.7M |
|
|
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
| $54M | 0.43% | 2,000,000 -250,000 | -11% | -$6.75M |
|
54
Zentalis Pharmaceuticals
ZNTL
$122M
| $47.6M | 0.38% | +991,174 | New | +$47.6M |
|
55
Generation Bio
GBIO
$40.4M
| $44.5M | 0.36% | +2,118,819 | New | +$44.5M |
|
56
Protagonist Therapeutics
PTGX
$3.67B
| $44.2M | 0.35% | 2,500,000 +1,000,000 | +67% | +$17.7M |
|
57
Equifax
EFX
$30.3B
| $43.9M | 0.35% | 255,344 -122,931 | -32% | -$21.1M |
|
|
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $42.7M | 0.34% | 715,000 -285,000 | -29% | -$17M |
|
59
United Therapeutics
UTHR
$13.8B
| $42.4M | 0.34% | 350,000 -15,000 | -4% | -$1.82M |
|
|
TVRD
60
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $39.3M | 0.31% | 2,300,000 | – | – |
|
61
Lantheus
LNTH
$3.73B
| $37.7M | 0.3% | +2,634,999 | New | +$37.7M |
|
62
Cytokinetics
CYTK
$4.23B
| $35.4M | 0.28% | 1,500,000 +875,000 | +140% | +$20.6M |
|
|
SAGE
63
DELISTED
Sage Therapeutics
SAGE
| $35.3M | 0.28% | 850,000 +175,000 | +26% | +$7.28M |
|
64
Arrowhead Research
ARWR
$3.05B
| $34.6M | 0.28% | 800,000 -200,000 | -20% | -$8.64M |
|
|
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $33.2M | 0.27% | +1,844,757 | New | +$33.2M |
|
|
AMRS
66
DELISTED
Amyris Inc.
AMRS
| $29.9M | 0.24% | +7,009,527 | New | +$29.9M |
|
67
TG Therapeutics
TGTX
$4.65B
| $29.2M | 0.23% | +1,500,000 | New | +$29.2M |
|
|
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
| $28.6M | 0.23% | 2,100,000 +45,514 | +2% | +$620K |
|
|
FSCT
69
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
| $27.7M | 0.22% | 1,305,000 +430,000 | +49% | +$9.12M |
|
70
Pliant Therapeutics
PLRX
$101M
| $27.6M | 0.22% | +850,801 | New | +$27.6M |
|
|
TECX
71
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $27.5M | 0.22% | 1,575,000 -150,000 | -9% | -$2.62M |
|
72
Karyopharm Therapeutics
KPTI
$61.7M
| $25.3M | 0.2% | 1,335,000 | – | – |
|
|
ADAP
73
Adaptimmune Therapeutics
ADAP
$15.6M
| $25M | 0.2% | +2,500,000 | New | +$25M |
|
74
Arcus Biosciences
RCUS
$1.13B
| $24.7M | 0.2% | +1,000,000 | New | +$24.7M |
|
75
Veracyte
VCYT
$2.39B
| $22M | 0.18% | 850,000 -525,000 | -38% | -$13.6M |
|